91 results about "Type 1 diabetes" patented technology

The present invention relates to the use of an ROR inverse agonist or a pharmaceutically acceptable salt thereof for the preparation of a medicament for modulating ROR in a patient and / or for controlling autoimmune diseases and antibody-mediated rejection in a patient. The ROR-mediated diseases or autoimmune diseases include HIV, cancer, celiac disease, type 1 diabetes, Graves' disease (Graves' disease), inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, asthma, dermatitis, fatty liver disease, Crohn's disease (Crohn's disease), cardiovascular disease, inflammatory disease, nervous system disorders, multiple sclerosis, and the like. Acute respiratory distress syndrome and arteriosclerosis.

The present disclosure provides methods of amplifying tissue samples derived from humans for purposes of treating certain diseases. The method comprises: isolating a small amount of associated tissue by biopsy or other tissue acquisition methods; the tissue is amplified in vitro, and meanwhile, natural functions are reserved; and re-implanting the amplified tissue to alleviate human disease. One example includes ex vivo expansion of human pancreatic islet tissue and reimplantation of the expanded cells into an individual with Type 1 diabetes for treatment and long term relief or cure of disease.

The present disclosure is based in part on studies on novel tolerogenic peptides derived from a protein expressed by a pancreatic cell, which have been developed for use in antigen-specific immunotherapy for type 1 diabetes. Disclosed is a tolerogenic peptide capable of binding an MHC class II molecule independent of antigen processing for use in the treatment of type 1 diabetes, wherein the peptide is derived from a protein expressed by a pancreatic cell.

This invention discloses the application of IKK inhibitors in the preparation of drugs to restore pancreatic islet function. IKK inhibitors can effectively improve the problem of pancreatic β-cell differentiation defects, significantly increase the number of pancreatic β-cells, enhance the insulin secretion capacity of islet cells, and specifically upregulate the expression of key functional genes of pancreatic β-cells such as INS and NKX6.1 genes, thus repairing pancreatic islet function damage. This solves the technical problem that current treatments for type 1 diabetes can only replace insulin and relieve blood sugar symptoms, but cannot fundamentally repair pancreatic islet function. IKK inhibitors can be used to prepare drugs for the treatment of type 1 diabetes, providing a new approach for the clinical treatment of type 1 diabetes and possessing extremely high clinical translational value.

The invention discloses a preparation rich in polygonatum sibiricum polypeptide and application of the preparation in diabetes mellitus. The composition is prepared from rhizoma polygonati polypeptide, semeglutide, astaxanthin, an active agent and a ferroptosis mixture. Pharmacodynamic experiments show that in a diabetic mouse model, fasting blood glucose can be remarkably reduced, the serum insulin level can be increased, renal function indexes can be improved, and expression of NLRP3 inflammation pathway related proteins (NLRP3, Caspase-1 and IL-1beta) in pancreatic tissue can be remarkably inhibited. By integrating multiple mechanisms of blood glucose reduction, oxidation resistance, inflammation resistance, ferroptosis resistance and the like, multi-target collaborative intervention is realized, the pharmaceutical composition is remarkably superior to a single component in the aspects of blood glucose reduction, pancreas islet function protection and complication alleviation, and a new clinical strategy is provided for treatment of diabetes mellitus, especially type 1 diabetes mellitus.

The present invention relates to a composition comprising: an insulin derivative comprising at least one arylboronic acid or arylboroxol; and methionine, and to the use of the composition in the treatment of diabetes mellitus, including type 1 diabetes mellitus and type 2 diabetes mellitus.

Compositions are disclosed that include at least one protein disulfide isomerase or a biologically active fragment or variant thereof. Methods of producing and using the compositions are also disclosed. In particular (but not by way of limitation), methods are provided for reducing blood glucose, treating hyperglycemia, treating or reducing the occurrence of type 1 diabetes, treating or reducing the occurrence of type 2 diabetes, and / or treating or reducing the occurrence of type 3 diabetes (i.e., Alzheimer's Disease) by administering the composition that includes the at least one protein disulfide isomerase. The protein disulfide isomerase may be administered alone or may be administered simultaneously or sequentially with one or more additional active agents.

This invention is applied in the field of medicine, namely in endocrinology, and can be used in the treatment of type 1 diabetes. The invention proposes a combination containing a dipeptidyl peptidase 4 (DPP-4) inhibitor, a proton pump inhibitor (PP1), and γ-aminobutyric acid or γ-aminobutyric acid receptor agonist. This unique combination and dosage of drugs leads to the regeneration (recovery) of pancreatic β-cells, which occurs with a dramatic reduction in insulin requirements up to a total cessation of insulin in some individuals and is intended for the treatment of type 1 diabetes mellitus.

Provided herein are T cell epitopes associated with Type 1 diabetes. Also provided are antigen-presenting cells presenting such epitopes. T cells reactive to such epitopes, and related compositions and therapies.

The invention relates to therapeutic use of a glucokinase activator in combination with insulin or an insulin analogue. Methods of using glucokinase (GK) activators, particularly in combination with insulin or insulin analogs, are generally disclosed herein. In certain aspects, the disclosure provides methods of treating type 1 diabetes mellitus comprising administering a GK activator in combination with insulin or an insulin analogue. Also disclosed herein are uses of GK activators as medicaments, and the preparation of medicaments for such uses.

Provided are a method, system, and computer-readable medium for optimizing glycemic control of a diabetic subject having Type 1 diabetes through co-administration of sodium-glucose cotransporter inhibitors (SGLTi) and insulin. Such co-administration can be effected by, for example, regulating one or more administration reactions in view of analyses of continuous glucose monitoring (CGM) data that can be indicative of at least the potential for one or more glycemic events including hypoglycemia and hyperglycemia. The aforementioned regulation can occur according to a balancing of insulin infusion and provisioning of SGLTi so as to avoid the occurrence of either of such events while, at the same time, not promoting an instance of diabetic ketoacidosis (DKA).

The present application relates to the technical field of mRNA vaccine, and specifically discloses a proinsulin mRNA vaccine for protecting the function and quantity of pancreatic beta cells. The vaccine is composed of a lipid nanoparticle (LNP) and an mRNA wrapped by the LNP; the mRNA is an mRNA sequence encoding proinsulin, and all uridines in the mRNA sequence are replaced by N1-methyl pseudouridine. The mRNA vaccine of the present application realizes the dual protection of the quantity and function of pancreatic beta cells, compared with the existing intervention means which only focus on blood glucose control or immune regulation, the present application delays the occurrence process of type 1 diabetes from the root, and provides a new technical scheme and drug selection for the prevention and early intervention of type 1 diabetes.

The present invention relates to the role of purinergic receptors and ATP in T cell activation and autocrine system signaling. In one embodiment, the present invention provides a method of preventing or treating diabetes by administering a therapeutically effective inhibitor of ATP to a subject. In another embodiment, the present invention provides a method of preventing or treating fibrosis by administering a P2X7R soluble fusion protein. In another embodiment, the present invention provides a method of preventing or treating graft rejection by administering an inhibitor of P2X receptor signaling.

Described herein are methods of treating a human child including administering to the human child a compound selected from epigallocatechin gallate (EGCG), or a derivative thereof selected from epicatechin (EC), epigallocatechin (RGC) and epicatechin gallate (ECG), sulforaphane, olive oil, phylloquinone, quercetin, safranal, hydroxtyrosol, menaquinone-4, menaquinone-7, oleocanthal, peptide Ins-1 B9-23 19CAM22R-E, peptide Ins-1 B12-23-19CAM, peptide Ins-1 B12-23 19CAM22R-E, or a combination of any of the foregoing, wherein administration of the treatment is started between birth and six months of age. Also described are methods of treating a pregnant human or a nursing human mother who has recently given birth to an infant. Further described are insulin B chain mimotope peptides.

The disclosure provides polypeptides that specifically bind to HLA-DQ8 for treating Type 1 Diabetes (TID) and methods using same for reducing autoimmune destruction of pancreatic islet beta cells. In particular, the present disclosure relates to peptides containing at least one D-amino acid that are capable of blocking the presentation of antigenic islet peptides (e.g., lnsB:9-23) by HLA-DQ8, and to their uses, especially as it relates to the prevention and / or treatment of TID.

The present invention provides a compound having a PDHK inhibitory activity and useful for the treatment or prophylaxis of diabetes (type 1 diabetes, type 2 diabetes etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, cataract etc.), cardiac failure (acute cardiac failure, chronic cardiac failure), cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary disease, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension or Alzheimer disease. The present invention relates to a compound of the formula [I-a] or the formula [II], or a pharmaceutically acceptable salt thereof:wherein each symbol means the same as that described in the specification.

The present invention relates to a method for identifying a compound that modulates the C-terminal Src kinase (Csk) by modulating at least one of the following features: the expression, amount, stability, biological activity of the Csk protein, and / or the interaction of the Csk protein with the lymphocyte-specific tyrosine kinase (Lck) protein in a mammalian cell. The identified compound is particularly suitable for use in the prevention or treatment of an autoimmune disease, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), multiple sclerosis (MS), and type 1 diabetes (T1D), or an infection, such as a bacterial or viral infection, cancer, cardiovascular diseases, age-related diseases, and preferably for use in increasing cellular immunity against cancer cells.Further aspects of the invention relate to a screening method for screening for a compound and / or a pharmaceutical composition comprising the compound.

The invention relates to a new therapeutic agent for use in the prevention and / or treatment of diabetes, more particularly type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM). The new therapeutic agent is the "Damage suppressor" (DSUP) protein of a tardigrade organism of the genus Ramazzottius, preferably of the species Ramazzottius varieornatus. Also described are an isolated nucleic acid comprising a nucleotide sequence encoding the DSUP protein, an expression vector comprising said isolated nucleic acid, and a pharmaceutically acceptable vehicle containing internally said isolated nucleic acid or said expression vector, for use in the aforementioned therapeutic applications.

The present invention provides a composition comprising dendritic cells loaded with hHsp60sp, which dendritic cells are from a subject and have been fixed with paraformaldehyde (PFA). The subject may suffer from an autoimmune disease. Also provided are a method for preparing the composition; recombinant human cells comprising a heterologous gene encoding a fusion protein of HLA-E and hHsp60sp or B7sp, and expressing the fusion protein on the surface of the cells; a method for determining a percentage of maximum inhibition of testing the function of the HLA-E restricted CD8+ Treg cells from a subject, determining whether HLA-E restricted CD8+ Treg cells freshly isolated from a subject are defective, or determining whether defective HLA-E restricted CD8+ Treg cells from a subject are correctable; and a method for correcting defective HLA-E restricted CD8+ Treg cells, treating type 1 diabetes (T1D), or treating multiple sclerosis (MS).

The present application provides a use of a compound of formula (I) or a salt thereof in the manufacture of a medicament for the prevention or treatment of diabetes. In particular, a use of a compound of formula (Ia) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention or treatment of type 1 diabetes. The compounds of the present application have shown efficacy in in vitro cell assays and in a mouse model of type 1 diabetes, and have shown lower side effects in toxicology experiments.

The disclosure provides methods of preventing or treating Type 1 diabetes in a mammalian subject, reducing risk factors associated with Type 1 diabetes, and / or reducing the likelihood or severity of Type 1 diabetes. A method of attenuating an antigenic response in a mammal to at least one Type 1 diabetes related-antigen is also provided. The methods include sublingually administering an effective amount of an insulin-related peptide to a subject.

The present invention relates to a method of determining whether a subject is at risk of developing type 1 diabetes by determining the genetic risk score (GRS) of a subject. The present invention also comprises a pharmaceutical composition comprising insulin and a pharmaceutical acceptable carrier for use in a method for preventing type 1 diabetes in a subject having a genetic risk score as determined by the method mentioned above. Further, it encompasses a kit for use in a method of determining whether a subject is at risk of developing type 1 diabetes by determining the genetic risk score of a subject and a type 1 diabetes antigen for use in a method of immunizing a subject against type 1 diabetes having a genetic risk score as determined by the method mentioned above.

This invention discloses a type 1 diabetes vaccine based on autoantigen polypeptide molecules. The invention provides a series of immunogenic autoantigens as active ingredients in type 1 diabetes vaccines. This invention utilizes computer-simulated amino acid mutations of type 1 diabetes autoantigen sequences obtained from type 1 diabetes patients, supplemented by rational design based on the HLA-peptide-TCR ternary complex structure; targeted optimization enhances the binding affinity between the antigen and immune molecules, thereby achieving significant proliferation of type 1 diabetes-related CD4+ T lymphocytes. The autoantigens of this invention will serve as the basis for the development of type 1 diabetes vaccines in the form of artificially synthesized polypeptide molecules.

The application discloses a Smad5 mutant and application thereof in preventing and treating diabetes.The amino acid sequence of the Smad5 mutant is shown as SEQ NO ID:1.The application further discloses a nucleic acid encoding the Smad5 mutant, a recombinant expression vector containing the nucleic acid and a transformant.The application also includes the application of the nucleic acid, the recombinant expression vector containing the nucleic acid and the transformant in preparing a medicine for preventing and / or treating diabetes.The Smad5 mutant can improve the symptoms of type 1 diabetes and type 2 diabetes in vivo, and has no toxic side effects compared with conventional oral hypoglycemic drugs, and has no damage to the liver and kidney of patients.In addition, an agent for regulating acid-base balance is disclosed, which comprises baking soda alkaline drinking water; the agent can reduce blood sugar and relieve the symptoms of diabetes, and is more economical and convenient to operate for patients.

Among the various aspects of the present disclosure is the provision of methods for the treatment of type 1 diabetes by administering a brown adipose tissue (BAT)-secreted factor.

The present disclosure provides novel methods for increasing β-cell viability in islets by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to the islets. The disclosure also provides novel methods for treating a disease or condition in a subject, such as type 1 diabetes mellitus, by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to islets and transplanting the islets into the subject to treat the disease or condition. Kits and compositions including RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, are also provided to increase β-cell viability.

A method to prevent a disease, comprising: (1) administering a peptide comprising Delta6PV into a subject comprising a human or an animal; wherein the disease comprises one of more of Type 1 Diabetes, Rheumatoid arthritis, Lupus, Sjogren's syndrome, Multiple Sclerosis, Grave's disease, Giant cell artereitis, Ankylosing spondylitis, and Guillian Barre Syndrome; and (2) monitoring the disease in the subject.

The application provides application of PVRIG as a target point in preparation of a type 1 diabetes diagnosis and disease progression prediction product. Specifically, PVRIG has different expressions on the surfaces of NK cells, CD16 positive NK cells and CD16 negative NK cells in honeymoon patients and non-honeymoon patients of type 1 diabetes, and PVRIG has different expressions on the surfaces of NK cells, CD16 positive NK cells and CD16 negative NK cells in patients with faster islet function failure and patients with slower islet function failure of type 1 diabetes, so that PVRIG is closely related to type 1 diabetes, can be used as a new target point of type 1 diabetes, and provides a new way for diagnosis and disease progression prediction of type 1 diabetes.

The invention belongs to the technical field of diabetes risk prediction, and provides a method and system for predicting the diabetes risk of children prediabetic population, and the method comprises the following steps: S1, multi-modal data fusion collection: collecting children clinical data, biochemical indexes, dynamic blood glucose monitoring data and type 1 diabetes specific data; s2, feature engineering and model construction: carrying out feature engineering processing on the collected data, and extracting key indexes; s3, model training: performing risk prediction by using a machine learning model, and outputting a risk level and a confidence coefficient; s4, generating a personalized intervention scheme according to the risk level; according to the method, the accuracy and reliability of prediction are remarkably improved by combining comprehensive analysis of multi-modal data, key indexes can be accurately extracted through feature engineering and model training, risk prediction can be carried out by utilizing a machine learning model, and the development of child prediabetic people into diabetic patients is effectively delayed or prevented.